Immunotherapy represents a frontier in the treatment of cancer and other diseases. At ANRim, our scientists engineer lymphocytes to enhance the production of clinically valuable cells, ultimately benefiting patients.

• Chimeric Antigen Receptor (CAR) T Cell Therapy:

T cells are genetically modified to express chimeric antigen receptors (CARs), enabling them to recognize and attack specific cancer cells. Studies have demonstrated significant efficacy of this therapy in treating certain types of hematologic malignancies, such as leukemia and lymphoma.

• T Cell Receptor (TCR) Engineering:

Engineered T cells express specific T cell receptors (TCRs) that recognize cancer-specific antigens presented by major histocompatibility complex (MHC) molecules. Compared to CAR-T therapy, TCR engineering can be applied to a broader range of tumors, including solid cancers.

• Natural Killer (NK) Cell Therapy:

NK cells can be engineered to enhance their ability to recognize and kill cancer cells, often by introducing activating receptors or chimeric antigen receptors (CARs). Unlike T cells, NK cells do not require prior sensitization to target cells, enabling potentially faster immune responses.